September 27, 2019
MONROE, NY – Innovative Health Sciences LLC (“IHS” or the “Company”) has recently returned from the European Society of Immunodeficiencies (“ESID”) meeting in Brussels, Belgium. The four-day Congress was focused on Malignancy and PID and closed with IHS’ first Symposium held on Friday, September 20th, 2019.
The Symposium, hosted by IHS at Hotel Le Plaza in Brussels, provided an opportunity for the Company to present its mission and product design concepts to nurses, physicians, key opinion leaders, and industry professionals. The event was well attended and was filled with collaborative and productive group discussion.
Ma, the Company’s President and COO, said, “These types of events are integral for
industry innovation. It’s great to be able to share ideas and listen to unique
market needs and problems faced by clinicians and professionals from the use of
current infusion device technologies.
It’s an opportunity to generate a consensus for future infusion product
design and development that will meet the needs for the safe and effective drug
delivery of SCIg medication.” Andy Sealfon, CEO and Chief Technical Officer, presented
innovative concepts related to his research, design, and development of
infusion devices. Mr. Sealfon observed, “These industry collaborations are
essential and we are thankful that the industry professionals are ready to
openly share their experiences and develop innovative concepts that will create
a better quality of life for patients.”
Also in attendance was Peter Mok, Vice Chairman of AML Holdings Limited (“AML”). AML is a leading contract manufacturing company located in Hong Kong and has recently invested in IHS through its Associate Fund. This partnership brings state-of-the-art contract manufacturing capabilities and robust engineering resources for IHS’ new device design and development, in compliance with EU MDR, ISO13485:2016 and US FDA QSR regulations. Jeff Craven, General Counsel and Chief Commercial Officer, stated, “The spirit of collaboration tonight means very good things for IHS’ growth and business initiatives. We are looking forward to future industry partnerships and building on our current relationships throughout the home infusion industry.”
About Innovative Health Sciences
Innovative Health Sciences, LLC (located in Monroe, NY), is a newly established medical device company focused on developing and commercializing the home infusion device industry using state-of-the-art, proprietary technology, and innovative Intellectual Property (“IP”), with the goal of creating a “one-stop shop” solution for the home infusion industry. IHS intends to optimize the infusion of medications by focusing on patient outcomes and perfecting the science and education of device technologies. IHS is currently developing new infusion technologies for SCIg treatment that will dramatically improve patient outcomes and will re-invent the home infusion therapy business. IHS intends to bridge the gap between infusion medications (Pharma) and infusion systems (Device Manufacturers) through the innovative combination of pharmacokinetics and fluidics.
Forward- Looking Statements
The statements contained herein do not guarantee future performance and undue reliance should not be placed on them. Such Forward Looking Statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied. These statements are based on management’s beliefs and theory. The Company undertakes no obligation to update Forward Looking Statements if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws.
Innovative Health Sciences, LLC